Showing results (91-100 of 131) with videos related to

Sort By:
Pageof 14
ACS Infectious Diseases|September 15, 2023
Covalent Macrocyclic Proteasome Inhibitors Mitigate Resistance in Plasmodium falciparumJohn M Bennett, Kurt E Ward, Ryan K Muir, et al.
ACS Infectious Diseases|February 11, 2021
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19Kas Steuten, Heeyoung Kim, John C Widen, et al.
Blood|April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson, Peter L Greenberg, John M Bennett, et al.
American Journal of Hematology|June 16, 2018
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experienceChezi Ganzel, Zhuoxin Sun, Larry D Cripe, et al.
Haematologica|October 8, 2008
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsGhulam J Mufti, John M Bennett, Jean Goasguen, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Cancer|May 15, 2023
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysisJames M Foran, Zhuoxin Sun, Catherine Lai, et al.
The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
The Lancet. Oncology|October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialCourtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
Pageof 14